When choosing the starting dosage strength of TRELEGY Ellipta, consider:1
- Patients’ disease severity
- Previous asthma therapy including ICS dosage
- Patients’ current control of asthma symptoms and risk of future exacerbations
TRELEGY Ellipta delivers three molecules (an ICS [fluticasone furoate], a LABA, [vilanterol] and a LAMA, [umeclidinium]) in a single inhaler, once daily.1
The Ellipta device has been designed for simplicity and ease of use, minimising usage errors.2,3
When choosing the starting dosage strength of TRELEGY Ellipta, consider:1
TRELEGY Ellipta (FF/UMEC/VI) 100/62.5/25 mcg
TRELEGY Ellipta (FF/UMEC/VI) 200/62.5/25 mcg
(TRELEGY Ellipta 200 is only approved in asthma, not COPD)
Key steps to use the TRELEGY Ellipta inhaler1
Poor inhaler technique may lead to treatment failure in asthma.²
Adapted from van der Palen et al. 2016²
Single-visit, placebo inhaler, crossover comparison in patients naïve to Ellipta and the comparator inhaler
*Critical errors are defined as errors that are likely to result in no, or minimal, medication being delivered to the lung²
**Statistically significant only between Ellipta and Turbuhaler in sub-study 3 (p<0.001)²
Contraindications: Hypersensitivity to the active substances or to any of the excipients (lactose monohydrate and magnesium stearate) or patients with severe milk-protein allergy. Warnings & Precautions: Asthma: Should not be used to treat acute asthma symptoms or an acute exacerbation in COPD for which a short-acting bronchodilator is required. COPD: Should not be used to treat an acute exacerbation in COPD for which a short-acting bronchodilator is required. Patients should not stop therapy with Trelegy Ellipta, in asthma or COPD, without physician supervision since symptoms may recur after discontinuation. Discontinue Trelegy if paradoxical bronchospasm occurs and institute alternative therapy if necessary. Cardiovascular effects, such as cardiac arrhythmias e.g. atrial fibrillation and tachycardia, may be seen after the administration of muscarinic receptor antagonists or sympathomimetics, use with caution in patients with unstable or life-threatening cardiovascular disease. Monitor patients with moderate to severe hepatic impairment for systemic corticosteroid-related adverse reactions and the 100/62.5/25 micrograms dose should be used. Systemic effects may occur, particularly at high doses for long periods, but much less likely than with oral corticosteroids. Possible systemic effects include HPA suppression, decrease in bone mineral density, cataract, glaucoma, central serous chorioretinopathy and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression. Use with caution in patients with urinary retention, narrow angle glaucoma, pulmonary tuberculosis or with chronic or untreated infections. hyperglycaemia and severe hepatic impairment. Consider risk factors for pneumonia in patients with COPD before prescribing, and re-evaluate treatment if pneumonia occurs. Adverse Reactions: Very Common: Nasopharyngitis. Common: Urinary tract infection, sinusitis, pharyngitis, upper respiratory tract infection, headache, cough, oropharyngeal pain, dysphonia, constipation, pneumonia, bronchitis, rhinitis, influenza, candidiasis of mouth and throat, arthralgia, back pain, viral respiratory tract infection. Uncommon: dry mouth, dysgeusia, atrial fibrillation, supraventricular tachyarrythmia, tachycardia, fractures.
Version number: GDS12/IPI13a(SI)
Footnotes
COPD, chronic obstructive pulmonary disease; FF, fluticasone furoate; ICS, inhaled corticosteroid; LABA, long-acting β₂-adrenergic agonist; LAMA, long-acting muscarinic antagonist; MDI, metered dose inhaler; NS, not statistically significant; UMEC, umeclidinium; VI, vilanterol
TRELEGY Ellipta is indicated for the maintenance treatment of asthma in patients aged 18 years and older who are not adequately controlled with a combination of a LABA and ICS.1
References
Adverse events should be reported. For reporting of adverse events, please write to sg.drugsafety@gsk.com.
© 2024 GSK Group of Companies or its licensor
Trademarks are the property of their respective owners
PM-SG-FVU-WCNT-240018 | April 2024